nach oben

Targeted Oncology

Erschienen in:

02.06.2016 | Original Research Article

Effect of AURKA Gene Expression Knockdown on Angiogenesis and Tumorigenesis of Human Ovarian Cancer Cell Lines

verfasst von: Cong Wang, Qin Yan, Minmin Hu, Di Qin, Zhenqing Feng

Erschienen in: Targeted Oncology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Ovarian cancer is one of the most common malignant gynecological cancers. Higher expression of AURKA has been found in immortalized human ovarian epithelial cells in previous studies, implying the relationship between AURKA and ovarian cancer pathogenesis.

Aim

We investigated the effect of AURKA on angiogenesis and tumorigenesis of human ovarian cancer cells.

Methods

Firstly, the expression of AURKA in HO8910 and SKOV3 ovarian cancer cell lines was knocked down using a vector expressing a short hairpin small interfering RNA (shRNA). Next, the effect of knockdown of AURKA on cell angiogenesis, proliferation, migration, and invasion was determined by microtubule formation assay, proliferation assay, transwell migration, and invasion assays. In addition, the effect of AURKA knockdown on angiogenesis and tumorigenesis was also determined in a chicken chorioallantoic membrane (CAM) model and in nude mice.

Results

The results of the microtubule formation assay indicated that knockdown of AURKA significantly inhibited ovarian cancer cell-induced angiogenesis of endothelial cells compared to its control (P < 0.001). Knockdown of AURKA also significantly inhibited cell proliferation, migration, and invasion of HO8910 and SKOV3 cells in vitro. Furthermore, the Matrigel plug assay showed that knockdown of AURKA significantly repressed ovarian cancer cell-induced angiogenesis in nude mice (P < 0.05), and the CAMs model also showed that AURKA knockdown significantly attenuated the angiogenesis (P < 0.001) and tumorigenesis (P < 0.001) of HO8910 cells compared to the control. Finally, the tumorigenicity assay in vivo further indicated that AURKA shRNA reduced tumorigenesis in nude mice inoculated with ovarian cancer cells (P < 0.001).

Conclusions

These results suggest the potential role of AURKA in angiogenesis and tumorigenesis of ovarian cancer, which may provide a potential therapeutic target for the disease.

Nur mit Berechtigung zugänglich

Jemal A et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMed

Tan DS, Agarwal R, Kaye SB. Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 2006;7(11):925–34.CrossRefPubMed

Chornokur G et al. Global ovarian cancer health disparities. Gynecol Oncol. 2013;129(1):258–64.CrossRefPubMed

Abiko K et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res. 2013;19(6):1363–74.CrossRefPubMed

Akutagawa N et al. Expression of vascular endothelial growth factor and E-cadherin in human ovarian cancer: association with ascites fluid accumulation and peritoneal dissemination in mouse ascites model. Jpn J Cancer Res. 2002;93(6):644–51.CrossRefPubMed

Fu J et al. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res. 2007;5(1):1–10.CrossRefPubMed

Marumoto T, Zhang D, Saya H. Aurora-A - a guardian of poles. Nat Rev Cancer. 2005;5(1):42–50.CrossRefPubMed

Wang X et al. Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene. 2006;25(54):7148–58.CrossRefPubMed

Bischoff JR et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 1998;17(11):3052–65.CrossRefPubMedPubMedCentral

10.

Zhou H et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet. 1998;20(2):189–93.CrossRefPubMed

11.

Zhang Z et al. Activation of BTAK expression in primary ovarian surface epithelial cells of prophylactic ovaries. Mod Pathol. 2007;20(10):1078–84.CrossRefPubMed

12.

Do TV et al. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion. Oncogene. 2014;33(5):539–49.CrossRefPubMed

13.

Jeng YM et al. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res. 2004;10(6):2065–71.CrossRefPubMed

14.

Kamada K et al. Amplification/overexpression of Aurora-A in human gastric carcinoma: potential role in differentiated type gastric carcinogenesis. Oncol Rep. 2004;12(3):593–9.PubMed

15.

Tatsuka M et al. Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene. 2005;24(6):1122–7.CrossRefPubMed

16.

Rojanala S et al. The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Mol Cancer Ther. 2004;3(4):451–7.PubMed

17.

Yakushijin Y, Hamada M, Yasukawa M. The expression of the aurora-A gene and its significance with tumorgenesis in non-Hodgkin’s lymphoma. Leuk Lymphoma. 2004;45(9):1741–6.CrossRefPubMed

18.

Macarulla T, Ramos FJ, Tabernero J. Aurora kinase family: a new target for anticancer drug. Recent Pat Anticancer Drug Discov. 2008;3(2):114–22.CrossRefPubMed

19.

Ren J et al. Tumor markers for early detection of ovarian cancer. Expert Rev Mol Diagn. 2010;10(6):787–98.CrossRefPubMed

20.

Dominguez-Brauer C et al. Targeting mitosis in cancer: emerging strategies. Mol Cell. 2015;60(4):524–36.CrossRefPubMed

21.

Hamada M et al. Aurora2/BTAK/STK15 is involved in cell cycle checkpoint and cell survival of aggressive non-Hodgkin’s lymphoma. Br J Haematol. 2003;121(3):439–47.CrossRefPubMed

22.

Qin D et al. Activation of PI3K/AKT and ERK MAPK signal pathways is required for the induction of lytic cycle replication of Kaposi’s sarcoma-associated herpesvirus by herpes simplex virus type 1. BMC Microbiol. 2011;11:240.CrossRefPubMedPubMedCentral

23.

Aranda E, Owen GI. A semi-quantitative assay to screen for angiogenic compounds and compounds with angiogenic potential using the EA.hy926 endothelial cell line. Biol Res. 2009;42(3):377–89.CrossRefPubMed

24.

Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307.CrossRefPubMedPubMedCentral

25.

Bobbin ML, Rossi JJ. RNA interference (RNAi)-based therapeutics: delivering on the promise? Annu Rev Pharmacol Toxicol. 2016;56:103–22.CrossRefPubMed

26.

Mendiola M et al. Aurora kinases as prognostic biomarkers in ovarian carcinoma. Hum Pathol. 2009;40(5):631–8.CrossRefPubMed

27.

Gritsko TM et al. Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res. 2003;9(4):1420–6.PubMed

28.

Moreno-Bueno G et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res. 2003;63(18):5697–702.PubMed

29.

Tanner MM et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res. 2000;6(5):1833–9.PubMed

30.

Ye Q, Lei L, Aili AX. Identification of potential targets for ovarian cancer treatment by systematic bioinformatics analysis. Eur J Gynaecol Oncol. 2015;36(3):283–9.PubMed

Titel: Effect of AURKA Gene Expression Knockdown on Angiogenesis and Tumorigenesis of Human Ovarian Cancer Cell Lines
verfasst von: Cong Wang
Qin Yan
Minmin Hu
Di Qin
Zhenqing Feng
Publikationsdatum: 02.06.2016
Verlag: Springer International Publishing
Erschienen in: Targeted Oncology / Ausgabe 6/2016
Print ISSN: 1776-2596
Elektronische ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-016-0436-7

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Effect of AURKA Gene Expression Knockdown on Angiogenesis and Tumorigenesis of Human Ovarian Cancer Cell Lines

Abstract

Background

Aim

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background

Aim

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial

Annual Congress of the European Society for Medical Oncology (ESMO): Copenhagen, Denmark; 7–11 October 2016

Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis

Will Testicular Germ Cell Tumors Remain Untargetable?

Anti-EGFR Agents: Current Status, Forecasts and Future Directions

ᅟ

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie